<DOC>
	<DOC>NCT03104413</DOC>
	<brief_summary>The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male or female aged &gt;=18 to &lt;= 80 years at the Baseline Visit. Where locally permissible, subjects 16 to &lt; 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit Diagnosis of CD for at least 3 months prior to Baseline Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SESCD) Demonstrated intolerance or inadequate response to biologic therapy for CD If female, subject must meet the contraception recommendations Subject with a current diagnosis of ulcerative colitis or indeterminate colitis Subjects with unstable doses of concomitant Crohn's disease therapy Receipt of Crohn's disease approved biologic agents (within 8 weeks prior to Baseline), or any investigational biologic or other agent or procedure within minimally 35 days prior to the Baseline Prior exposure to p40 inhibitors (e.g., ustekinumab [Stelara]) or p19 inhibitors (e.g., risankizumab) Complications of Crohn's disease (strictures, stenosis, short bowel, etc) Having an ostomy or ileoanal pouch</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>BI 655066</keyword>
	<keyword>ABBV-066</keyword>
</DOC>